CYMABAY THERAPEUTICS INC's ticker is CBAY and the CUSIP is 23257D103. A total of 119 filers reported holding CYMABAY THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.54 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $729,889 | +41.2% | 48,953 | +3.7% | 0.01% | +66.7% |
| Q2 2023 | $516,982 | +294.6% | 47,213 | +11.7% | 0.00% | +200.0% |
| Q1 2022 | $131,000 | +5.6% | 42,257 | +14.7% | 0.00% | 0.0% |
| Q4 2021 | $124,000 | -10.1% | 36,834 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $138,000 | -18.3% | 37,936 | -2.3% | 0.00% | 0.0% |
| Q2 2021 | $169,000 | -7.7% | 38,837 | -3.8% | 0.00% | 0.0% |
| Q1 2021 | $183,000 | -20.8% | 40,372 | +0.3% | 0.00% | 0.0% |
| Q4 2020 | $231,000 | -23.0% | 40,265 | -2.8% | 0.00% | 0.0% |
| Q3 2020 | $300,000 | +102.7% | 41,420 | -2.2% | 0.00% | 0.0% |
| Q2 2020 | $148,000 | +146.7% | 42,362 | +3.9% | 0.00% | – |
| Q1 2020 | $60,000 | -29.4% | 40,777 | -5.5% | 0.00% | – |
| Q4 2019 | $85,000 | -61.9% | 43,133 | -0.8% | 0.00% | -100.0% |
| Q3 2019 | $223,000 | -29.0% | 43,497 | -0.7% | 0.00% | 0.0% |
| Q2 2019 | $314,000 | -37.8% | 43,799 | +15.2% | 0.00% | -50.0% |
| Q1 2019 | $505,000 | +65.6% | 38,005 | -2.0% | 0.00% | +100.0% |
| Q4 2018 | $305,000 | -29.6% | 38,794 | -0.8% | 0.00% | 0.0% |
| Q3 2018 | $433,000 | -15.9% | 39,093 | +1.8% | 0.00% | -50.0% |
| Q2 2018 | $515,000 | – | 38,389 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Foresite Capital Management IV, LLC | 1,787,094 | $26,645,572 | 14.80% |
| Lynx1 Capital Management LP | 994,161 | $14,822,941 | 9.80% |
| Octagon Capital Advisors LP | 3,073,750 | $45,829,613 | 7.04% |
| Saturn V Capital Management LP | 1,124,459 | $16,765,684 | 7.02% |
| Altium Capital Management LP | 800,000 | $11,928,000 | 6.22% |
| Affinity Asset Advisors, LLC | 1,129,376 | $16,838,996 | 4.74% |
| ACUTA CAPITAL PARTNERS, LLC | 418,000 | $6,232,380 | 4.18% |
| Cormorant Asset Management, LP | 3,850,000 | $57,403,500 | 3.35% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 590,000 | $8,796,900 | 2.67% |
| MPM BioImpact LLC | 610,770 | $9,106,581 | 2.43% |